Everolimus Exposure as a Predictor of Toxicity in RCC Patients in the Adjuvant Setting
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249)
Kidney Cancer 2019 Aug 07;3(2)111-118, TW Synold, M Plets, CM Tangen, EI Heath, GS Palapattu, PC Mack, MN Stein, MV Meng, P Lara, NJ Vogelzang, IM Thompson, CW RyanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.